Physician profile

Shruti Jolly

Radiation Oncology · Ann Arbor, MI

NPI 1780892174

$30,387.46

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$213.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $18,922.75 2019-2022
Varian Medical Systems, INC. $8,089.32 2019
Glaxosmithkline, LLC. $1,625.00 2021
Astrazeneca Uk Limited $1,331.57 2019
Reflexion Medical, INC. $213.00 2023 Reflexion Medical Radiotherapy System
Isoray, INC $106.18 2019
Novocure INC. $99.64 2019-2020

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Shruti Jolly

$30,387.46

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/1267660/shruti-jolly

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.